Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021669 · ClinicalTrials.gov registry record · Phase 2
Omega-3 for Depression and Other Cardiac Risk Factors - 2
A Phase 2 study of Depression, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT02021669 is a Phase 2 study of Depression that has completed, run by Washington University School of Medicine. The registered enrollment target is 144 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02021669, a Phase 2 study of Depression, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omega-3 supplement
Study Locations (1)
Missouri
- Washington University Medical Center - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2018-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021669
The ClinicalTrials.gov registry entry for NCT02021669 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (82% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02021669 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT02021669 about?
NCT02021669 is a clinical study titled "Omega-3 for Depression and Other Cardiac Risk Factors - 2". The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).
What is the current status of trial NCT02021669?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2014-05-14. Estimated completion is 2018-09-13.
What conditions does trial NCT02021669 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT02021669?
The interventions under investigation include: Placebo (DRUG), Omega-3 supplement (DRUG).
Who is sponsoring clinical trial NCT02021669?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02021669 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.